In summary, our study supports the concept that dynamic changes in the expression of the biomarkers CD38, HLA-DR and Ki67 on MTB-specific CD4+ T-cells over 6 months of TB treatment can be used to monitor TB treatment outcomes among HIV-positive patients. This evidence concerns the gene CD4 and tuberculosis.